Boundless Bio, Inc.
Boundless Bio, Inc. (BOLD): 9 pipeline candidates · ~18 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.0 months
D/E 0.63 · 0% dilution
Lead: Phase 1
9 candidates
N/A
N/A
A transparent, data-derived signal for Boundless Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$32.2M
Cash
$18.0M
Quarterly Burn
$15.0M
Runway
18.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$8.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,695,455 | $3.0M |
| citadel advisors llc | 1,342,131 | $1.5M |
| vanguard capital management llc | 1,194,384 | $1.3M |
| sectoral asset management inc | 678,574 | $746K |
| wellington management group llp | 556,233 | $612K |
| renaissance technologies llc | 399,000 | $439K |
| alyeska investment group, l.p. | 300,000 | $330K |
| sio capital management, llc | 163,679 | $180K |
| geode capital management, llc | 127,576 | $140K |
| millennium management llc | 99,875 | $110K |
Showing top 10 of 33 institutional holders of Boundless Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Boundless Bio, Inc.'s pipeline?
Boundless Bio, Inc. (BOLD) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Boundless Bio, Inc.'s lead drug candidate?
Boundless Bio, Inc.'s most advanced tracked candidate is BBI-355 (Phase 1) for Triple Negative Breast Cancer (TNBC).
What is Boundless Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Boundless Bio, Inc. has approximately 18.0 months of cash runway.
What is Boundless Bio, Inc.'s market capitalization?
Boundless Bio, Inc.'s market capitalization is approximately $32.2M.
Who is the CEO of Boundless Bio, Inc.?
Mr. Zachary D. Hornby is the chief executive officer of Boundless Bio, Inc. (BOLD).
Get the full picture on Boundless Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.